One state decided to take a hard line stance against Gilead’s pricey hep C drugs last year. And this decision may end up turning into a huge windfall for AbbVie’s rival therapy. Here’s why.
One state decided to take a hard line stance against Gilead’s pricey hep C drugs last year. And this decision may end up turning into a huge windfall for AbbVie’s rival therapy. Here’s why.